William Waddill - Jan 9, 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Director
Signature
/s/William Waddill
Stock symbol
ARWR
Transactions as of
Jan 9, 2023
Transactions value $
-$96,000
Form type
4
Date filed
1/11/2023, 07:23 PM
Previous filing
Jun 13, 2022
Next filing
Jan 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$96K -3.2K -9.95% $30.00 29K Jan 9, 2023 Direct F1
transaction ARWR Common Stock Award $0 +7.87K +27.17% $0.00 36.8K Jan 10, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Common Stock Award $0 +4.59K $0.00 4.59K Jan 10, 2023 Common Stock 4.59K $33.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date.
F3 Represents options, which will vest in one installment on the first anniversary of the grant date.